These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32444159)

  • 1. Elevated Lipoprotein-Associated Phospholipase A2 is Valuable in Prediction of Coronary Slow Flow in Non-ST-Segment Elevation Myocardial Infarction Patients.
    Liang Q; Lei X; Huang X; Fan L; Yu H
    Curr Probl Cardiol; 2021 Mar; 46(3):100596. PubMed ID: 32444159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Lipoprotein-Associated Phospholipase A2 Level Is an Independent Predictor of High Thrombus Burden in Patients With Acute ST-segment Elevation Myocardial Infarction.
    Wu X; Zhang Y; Wu Z; You W; Liang F; Ye F; Chen S
    Int Heart J; 2016 Dec; 57(6):689-696. PubMed ID: 27818473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between serum inflammatory cytokine levels and fibrous cap thickness of fibrofatty plaque in coronary culprit lesions].
    Zhong Y; Ye F; You W; Wu ZM
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jul; 45(7):566-571. PubMed ID: 28738484
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow.
    Ding YD; Pei YQ; Wang R; Yang JX; Zhao YX; Liu XL; Shen H; Ma Q; Zhang S; Ge HL
    BMC Cardiovasc Disord; 2020 May; 20(1):248. PubMed ID: 32460702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study.
    Yang F; Ma L; Zhang L; Wang Y; Zhao C; Zhu W; Liang W; Liu Q
    Heart Vessels; 2019 Oct; 34(10):1608-1614. PubMed ID: 30963302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial function after ST-elevation myocardial infarction in patients with high levels of high-sensitivity CRP and Lp-PLA
    Kandhai-Ragunath JJ; de Wagenaar B; Doelman C; van Es J; Jørstad HT; Peters RJG; Doggen CJM; von Birgelen C
    Cardiovasc Revasc Med; 2017; 18(3):202-206. PubMed ID: 28110894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein associated- phospholipase A2 in STEMI vs. NSTE-ACS patients: a marker of cardiovascular atherosclerotic risk rather than thrombosis.
    Verdoia M; Rolla R; Gioscia R; Rognoni A; De Luca G;
    J Thromb Thrombolysis; 2023 Jul; 56(1):37-44. PubMed ID: 37022507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum lipoprotein-associated phospholipase A2 predicts the formation of carotid artery plaque and its vulnerability in anterior circulation cerebral infarction.
    Yang Y; Xue T; Zhu J; Xu J; Hu X; Wang P; Kong T; Yan Y; Yang L; Xue S
    Clin Neurol Neurosurg; 2017 Sep; 160():40-45. PubMed ID: 28644968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.
    Woudstra P; Damman P; Kuijt WJ; Kikkert WJ; Grundeken MJ; van Brussel PM; Stroobants AK; van Straalen JP; Fischer JC; Koch KT; Henriques JP; Piek JJ; Tijssen JG; de Winter RJ
    PLoS One; 2014; 9(5):e96251. PubMed ID: 24788873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
    Stankovic S; Asanin M; Trifunovic D; Majkic-Singh N; Miljković A; Ignjatovic S; Mrdovic I; Matic D; Savic L; Ostojic M; Vasiljevic Z
    Clin Lab; 2012; 58(11-12):1135-44. PubMed ID: 23289182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).
    Möckel M; Müller R; Vollert J; Müller C; Danne O; Gareis R; Störk T; Dietz R; Koenig W
    Clin Res Cardiol; 2007 Sep; 96(9):604-12. PubMed ID: 17593313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between the D166E polymorphism of the lipoprotein associated phospholipase A2 and risk of myocardial infarction.
    Zhang MM; Zhang CG; Yang CJ; Zhao P; Li YL
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3960-3966. PubMed ID: 31115024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain.
    Dullaart RP; van Pelt LJ; Kwakernaak AJ; Dikkeschei BD; van der Horst IC; Tio RA
    Clin Chim Acta; 2013 Sep; 424():136-40. PubMed ID: 23756128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Relationship Between the Level of Serum ESM-1 and Lp-PLA2 in Patients With Acute ST-Segment Elevation Myocardial Infarction.
    Wei P; Zong B; Liu X; Zhang M; Yang C; Wang H; Fu Q; Wang L; Cao B
    Clin Transl Sci; 2021 Jan; 14(1):179-183. PubMed ID: 32710501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction.
    Elkind MS; Leon V; Moon YP; Paik MC; Sacco RL
    Stroke; 2009 Oct; 40(10):3233-7. PubMed ID: 19644070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease.
    Mourouzis K; Siasos G; Oikonomou E; Zaromitidou M; Tsigkou V; Antonopoulos A; Bletsa E; Stampouloglou P; Vlasis K; Vavuranakis M; Tousoulis D
    Lipids Health Dis; 2021 Feb; 20(1):12. PubMed ID: 33583415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein-Associated Phospholipase A2 in Cardiac Disease: a Potential Early Biomarker of Unstable Coronary Artery Disease.
    Li J; Zhou Z; Niu X; Li H
    Clin Lab; 2020 May; 66(5):. PubMed ID: 32390386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.
    Buchner S; Debl K; Barlage S; Griese D; Fredersdorf S; Jeron A; Lubnow M; Müller T; Muders F; Holmer S; Riegger GA; Luchner A
    Clin Chem Lab Med; 2010 Jun; 48(6):875-81. PubMed ID: 20441480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of initial Lp-PLA2, NT-proBNP, and peripheral blood-related ratios for heart failure after early onset infarction in patients with acute myocardial infarction.
    Li X; Zhang T; Xing W
    Am J Transl Res; 2024; 16(7):2940-2952. PubMed ID: 39114672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.